Indaptus Therapeutics, Inc.
INDP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001857044
No open-market purchases or sales by Indaptus Therapeutics, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q3 2026, worth $2.18M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 20, 2026
- $433.2M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ3 2026, +12 vs. previous quarter
- 21
- 13F valueReported value at the end of Q3 2026
- $2.18M
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$20.8M
- No comparable prior period
- Free cash flow, FY2025
- –
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 1.14M
- Shares sold short
- Change
- +282.6K
- +33.0% vs. previous
- Days to cover
- 3.96
- At average daily volume
Superinvestors holding INDP, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding INDP at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Indaptus Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 24, 2026 (view filing) | Mar 23 | 1 day | Lazar David E.Director | SSale | −108.9M | – | – | –0 after | Derivative2 lots |
| Aug 16, 2023 (view filing) | Aug 10-14 | 6 daysLate | Anderson Glen R.10% Owner | PPurchase | +103.4K | $2.09 | +$216.4K | +9.5%1.19M after | 3 lots |
| Dec 19, 2022 (view filing) | Jan 31-Dec 1 | 322 daysLate | Litchev Boyan VesselinovChief Medical Officer | PPurchase | +1.15K | $2.19 | +$2.52K | New position1.15K after | 4 lots |
| Nov 22, 2022 (view filing) | Nov 18-21 | 4 days | Meckler Jeffrey ACEO and Director | PPurchase | +10.0K | $1.89 | +$18.9K | +15.3%75.4K after | 2 lots |
| Sep 12, 2022 (view filing) | Sep 8 | 4 days | Meckler Jeffrey ACEO and Director | PPurchase | +10.3K | $2.80 | +$28.9K | +18.7%65.4K after | |
| Sep 9, 2022 (view filing) | Sep 7 | 2 days | Linscott Walt AddisonChief Business Officer | PPurchase | +150 | $2.62 | +$393 | New position150 after | |
| Sep 8, 2022 (view filing) | Sep 6-7 | 2 days | Meckler Jeffrey ACEO and Director | PPurchase | +9.69K | $2.56 | +$24.8K | +21.4%55.1K after | 2 lots |
| Jun 7, 2022 (view filing) | Jun 6 | 1 day | Meckler Jeffrey ACEO and Director | PPurchase | +19.7K | $2.63 | +$51.9K | +76.9%45.4K after | |
| Feb 2, 2022 (view filing) | Jan 31-Feb 1 | 2 days | Newman Michael JamesCSO and Director | SSale | −20.0K | $5.00 | −$100.0K | −1.4%1.37M after | 2 lots |
| Nov 19, 2021 (view filing) | Nov 18 | 1 day | Meckler Jeffrey ACEO and Director | PPurchase | +11.2K | $5.82 | +$65.1K | +77.4%25.6K after |
Top 10 13F holders, Q3 2026
See all 21 holdersThe largest institutional positions in Indaptus Therapeutics, Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 195,620 | $449.9K | 0.00% | +139,150+246.4% | Added |
| Vanguard Capital Management LLC | 135,978 | $312.7K | 0.00% | +102,326+304.1% | Added |
| Jane Street Group, LLC | 86,484 | $198.9K | 0.00% | +32,673+60.7% | Added |
| UBS Group AG | 83,363 | $191.7K | 0.00% | +82,885+17,340.0% | Added |
| Marshall Wace, LLP | 77,847 | $179.0K | 0.00% | +77,847 | New |
| Millennium Management LLC | 72,073 | $165.8K | 0.00% | +60,487+522.1% | Added |
| Vanguard Fiduciary Trust Co | 65,315 | $150.2K | 0.00% | +51,348+367.6% | Added |
| State Street Corp | 63,866 | $146.9K | 0.00% | +63,866 | New |
| Virtu Financial LLC | 34,659 | $80.0K | 0.00% | +34,659 | New |
| Jump Financial, LLC | 27,662 | $63.6K | 0.00% | +27,662 | New |
Holders of 5% or more of INDP
See all 7 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Indaptus Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Lazar David E. | 13D/A | 47.93%2.06M shares | −50.07 ppfrom 98.00% | Mar 2, 20262 filings | Mar 24, 2026 | SEC |
| Yao Yun | 13D/A | 27.34%42.0M shares | −4.17 ppfrom 31.51% | Mar 30, 20264 filings | Oct 22, 2026 | SEC |
| Sino Lion Ventures Ltd | 13D/A | 25.32%38.9M shares | −3.87 ppfrom 29.19% | Jun 26, 20262 filings | Oct 22, 2026 | SEC |
| Meckler Jeffrey A | 13D/A | 12.70%273.1K shares | – | Oct 10, 20243 filings | Dec 30, 2025 | SEC |
| Dai Junyi | 13D/A | 7.33%11.3M shares | −1.11 ppfrom 8.44% | Jun 26, 20262 filings | Oct 22, 2026 | SEC |